

# **Corporate Briefing Session**

GSK Consumer Healthcare Pakistan Limited



Company Brief and Key Facts Our Vision, Values and Strategy **Key Financials Questions and Answers** 



**Company Brief and Key Facts** 

## **Company Brief and Key facts**





- ➤ Post merger, operations of both companies being carried on by one legal entity only: GSK Consumer Healthcare Pakistan Limited.
- Market Capitalization as at September 30<sup>th</sup> is PKR 27.7 billion
- Sept YTD Earning Per share of 8.32 rupees, depicting growth of 9.6% over same period last year.
- ➤ GSK CHC have a Total Market Share of \*17.7%. Key brands include Panadol, CaC 1000 plus and Sensodyne contributing 81% in total turnover.

## **Board Committees & Key Roles**



#### **Audit Committee**

- Syed Anwar Mahmood (Chairman)
- •M.Z. Moin Mohajir
- Talal Javed Ahmed
- Mariam Maqsood (Secretary)

# Human Resource and Remuneration Committee

- Syed Anwar Mahmood (Chairman)
- •M.Z. Moin Mohajir
- Talal Javed Ahmed
- Farqaleet Iqbal (Secretary)

# Integration Supply & Network Optimization Committee

- Oussama Abbas (Chairman)
- Dilawar Meghani
- Sohail Ahmed Matin
- •Talal Javed Ahmed
- Irfan Qureshi (Secretary)

#### **Management Committee**

- Sohail Ahmed Matin (CEO)
- Ahmed Jamil Baloch
- •Dilawar Meghani
- Mashal Mohammad
- Faisal Rafiq
- Khurram Khan
- Shoaib Raza
- Saleem Khilji
- Mazhar Shams
- Muzna Hussain
- Sadia Tabassum
- ·Hina Sadiq

#### Company Secretary

 Mashal Mohammad

# Chief Financial Officer

Dilawar Meghani

# Chief Internal Auditor

Mariam Magsood

#### Bankers

- Citibank N.A.
- Standard Chartered Bank

#### **Auditors**

 Yousuf Adil, Chartered Accountants

#### **Legal Advisors**

 Hashmi & Hashmi Advocates and Solictors

# **Our Local Footprint**





West Wharf Office



Jamshoro Factory

#### **Registered Office:**

35-Dockyard Road, West Wharf, Karachi

#### **Sales Offices:**

Karachi – B 63, 65, Estate Avenue, SITE Lahore – 880 B, Faisal Town Islamabad – Aleem House, Plot 409, Sector I9, Industrial Area

#### **Factory:**

- GSK CHC acquired the manufacturing facility of GSK OTC in Jamshoro, after the Court Order was received in December 2018.
- State of the art facility for manufacturing and packaging.
- Serving to Pakistan, Vietnam and Philippines markets.

#### **Brands Portfolio**



#### **FMCG**

(Represents 16% business)

**Oral Care** 

**Skin Health** 



**SpectraBAN** 







# **OVER THE COUNTER (Regulated by DRAP)**

(Represents 84% business)

**Nutrition & Digestive** 

**Skin Health** 



**Pain Relief** 




















# **Industry Landscape**







**Our Vision, Values and Strategy** 

## Our Values & Expectations are at the Heart of Everything We Do





## **Our Purpose, Vision and Strategy**



## **Purpose**

To help people do more, feel better, live longer

### **Vision**

To be one of the world's most innovative, best performing and trusted consumer healthcare companies

# **Strategy**



# **Innovation**

- Brilliant execution of launches
- Strong patient and payer focused pipeline
- The most competitive claims and labels



### **Performance**

Sustained industry-leading growth with competitive costs, margin and cash flow



### **Trust**

- Reliable supply
- Improved reputation
- Highly engaged employees

#### **Innovations**









Panadol CF Day
Expanding the Respiratory
Business

**Sensodyne Herbal** 

**Parodontax Herbal** 

Entering the growing Herbal Segment in Oral Health Category

## **Key Brands Performance**



## **Top 3 Brands contribute 81% to Total turnover**





**42%** Contribution GSK Share **21.5% 17%** Volume Growth



#### **Prescribed Calcium supplement**



27% Contribution GSK Share 45.3% 21%Volume Growth





13% Contribution
GSK Share 16.5%
12% Volume Growth

## **Key Campaigns**



### **Panadol**



Panadol Lady Doctor Campaign keeping brand top of mind for consumers

Always-On Digital to build reach, relevance and engagement

PANADOL FORTE









Building relevance for Panadol Children's range

### **Calcium Awareness**

Launched #1000WaysICan campaign to drive top of mind awareness



Clutter Breaking assets for TV, Radio & Digital





Amplification of awareness campaign through web series and PR

## Sensodyne

Drove Sensodyne Herbal on multiple platforms for max reach and conversions





with new copies & Love Food Again Campaign amplification



## **Key Performance Highlights and Trust Factors**





- Delivered 23% sales growth during first nine months ending September 2020.
- Captured overall Market share of \*17.7% in total operating market. +2.4% vs LY
- Increased Oral Care numeric distribution by driving smaller size SKUs in General Trade.



- Evolved a new RTM structure; One face to Pharmacy and separate FMCG hybrid model.
- Successful deployment of SAP despite remote working with no business disruption.
- Rolled out new Commex Structure to bring a step change in Commercial capability.



- Established outsourced E2E national distribution models for tail brands including PSE portfolio.
- Reorganized, consolidated & strengthened Expert function to drive efficiency & increase coverage.
- Strong delivery through eCommerce channel by integrating into Modern Trade structure.



- Sales forecast Accuracy continues to be a challenge due to Covid-19. Focusing on OTIF to ensure availability.
- Marketing Authorisations successfully transferred for Panadol Tablets and Panadol Liquids from GSK Pharma Pakistan Limited to GSK Consumer Healthcare Pakistan Limited.

### **GSK CH's response to COVID**



#### **Response in COVID**

Quickly responded to changing market dynamics



Covid Awareness campaign by Panadol #staysafe


Dentist Awareness
message on
Oral Health habits
by Sensodyne during
COVID



Expert team started
Remote Detailing to
reach doctors;
hosted online conferences

#### People Safety

Ensured team and front line workers were safe



Protective Kits given to
Doctors, Sales &
Expert team for their safety



Protective shields installed in medical stores for safety of pharmacists

#### **Supply Chain Operations**

Put customers & consumers first



Strong BCPs put in place to cater to upsurge in demand of Panadol & CaC

Additional inventory
of RM/PM
purchased to support
continuous operations





BCPs agreed with LSPs to ensure Finished Goods are delivered to customers on time and in full



**Key Financial** 

# **Key Financial Highlights**



#### YTD September 2020

Net Sales
14,489
Million

Growth in Sales 23%

Gross margin 28%

\*OPEX
2,603
Million

(2% vs LY)

Profit before tax 1,381 million

(12% vs LY)

Earning per share Rs. 8.32

### YTD September 2019

Net Sales
11,812
Million

Gross margin 32%

OPEX 2,547 million


1,239
million

Earning per share Rs. 7.59

# Portfolio wise Sales – Sept YTD



#### Amounts in PKR million



<sup>\*</sup>Underlying growth is 16% excluding divestment of Oilatum, Horlicks & Physiogel.


# **Sales Contribution – Sept YTD**

Portfolio wise - Share






# 2020: PORTFOLIO SHARE



# **Revenue Distribution**









Balance Sheet Ratios	September 30, 2020	September 30, 2019
Return on equity	20%	21%
Current Ratio	1.36	1.37
Quick Ratio	0.61	0.67
Inventory days	87	82
Receivables days	17	17
Payable days	21	24

## **Outlook and Challenges**





Unceasing spike in COVID cases, new regulations by government. Ultimate severity, duration and impact of the pandemic remain unknown.



Continuous currency devaluation negatively impacting the ability of business to distribute and invest more.



Face to face meetings with doctors to ensure better awareness of products is still a big challenge. Mix of F2F and remote detailing using digital forums in place.



Manufacturing continues to meet Panadol & CaC demand despite issues in sourcing APIs amid COVID. Material sourcing is a big challenge considering increased demand and prices.



Business Continuity Plan is in execution. Weekly Crisis Management Meeting (CMT) happening to address day to day challenges, ensure access to our patients to help; do more, feel better and live longer.

